(Q47817635)

5 February 2018

title

Interferon-alpha enhances CD95L-induced apoptosis of human malignant glioma cells (English)

1 reference

5 February 2018

author name string

Roth W

1

1 reference

5 February 2018

Wagenknecht B

2

1 reference

5 February 2018

Dichgans J

3

1 reference

5 February 2018

Weller M

4

1 reference

5 February 2018

publication date

1 July 1998

1 reference

5 February 2018

Journal of Neuroimmunology

published in

1 reference

5 February 2018

volume

87

1 reference

5 February 2018

issue

1-2

1 reference

5 February 2018

page(s)

121-129

1 reference

5 February 2018

Phase II evaluation of recombinant interferon alpha and BCNU in recurrent glioma.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900079-4

7 January 2021

Modulation of Apo-1/Fas (CD95)-induced programmed cell death in myeloma cells by interferon-alpha 2

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900079-4

7 January 2021

Involvement of an ICE-like protease in Fas-mediated apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900079-4

7 January 2021

Randomised, controlled study of intratumoral recombinant gamma-interferon treatment in newly diagnosed glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900079-4

7 January 2021

Intratumor administration of beta-interferon in recurrent malignant gliomas. A phase I clinical and laboratory study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900079-4

7 January 2021

Novel biologic therapies for malignant gliomas. Antiangiogenesis, immunotherapy, and gene therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900079-4

7 January 2021

Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900079-4

7 January 2021

Interferon-beta inhibits proliferation and progression through S phase of the cell cycle in five glioma cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900079-4

7 January 2021

Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900079-4

7 January 2021

Induction of growth suppression and modification of gene expression in multi‐drug‐resistant human glioblastoma multiforme cells by recombinant human fibroblast and immune interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900079-4

7 January 2021

FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death--inducing signaling complex

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900079-4

7 January 2021

Lethal effect of the anti-Fas antibody in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900079-4

7 January 2021

Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900079-4

7 January 2021

Immunochemotherapy of malignant glioma: synergistic activity of CD95 ligand and chemotherapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900079-4

7 January 2021

Taxol-mediated augmentation of CD95 ligand-induced apoptosis of human malignant glioma cells: association with bcl-2 phosphorylation but neither activation of p53 nor G2/M cell cycle arrest

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900079-4

7 January 2021

Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900079-4

7 January 2021

Lipoxygenase inhibitors block CD95 ligand-mediated apoptosis of human malignant glioma cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900079-4

7 January 2021

The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900079-4

7 January 2021

Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900079-4

7 January 2021

Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900079-4

7 January 2021

CD95 ligand: lethal weapon against malignant glioma?

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900079-4

7 January 2021

Long-term follow-up results of 175 patients with malignant glioma: importance of radical tumour resection and postoperative adjuvant therapy with interferon, ACNU and radiation

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900079-4

7 January 2021

Clinical effect of intra-arterial tumor necrosis factor-alpha for malignant glioma

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900079-4

7 January 2021

A pilot study of recombinant interferon beta (IFN-beta ser) in patients with recurrent glioma

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900079-4

7 January 2021

Intravenous recombinant interferon beta in patients with recurrent malignant gliomas: a phase I/II study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900079-4

7 January 2021

Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900079-4

7 January 2021

10.1016/S0165-5728(98)00079-4

Identifiers

DOI

1 reference

5 February 2018

1 reference

5 February 2018